查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1916895

依藥物類別、給藥途徑、劑型、通路和最終用戶分類的痛風治療市場－2026-2032年全球預測

Gout Medications Market by Drug Class, Route Of Administration, Dosage Form, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，痛風治療市場價值將達到 29.8 億美元，到 2026 年將成長至 31.5 億美元，到 2032 年將達到 45.6 億美元，複合年成長率為 6.23%。

關鍵市場統計數據
基準年 2025 29.8億美元
預計年份：2026年 31.5億美元
預測年份 2032 45.6億美元
複合年成長率 (%) 6.23%

對於當今的相關人員，這是對當前臨床、商業性和監管環境的精闢介紹，這些環境正在重塑全球痛風藥物格局。

痛風仍然是一個臨床意義重大且商業性前景廣闊的治療領域，其發展受到不斷演變的治療標準、新興的生物製藥製劑和小分子藥物以及不斷變化的患者就醫模式的影響。臨床醫生仍在努力平衡急性症狀管理和長期降尿酸策略，而支付者和採購團隊則要求提供證據，證明干預措施能夠帶來可衡量的療效和成本效益。藥物研發和醫療服務領域的創新融合，正在引入新的治療選擇，同時也增加了確定最佳治療方案的複雜性。

變革性的轉變正在改變患者照護路徑、創新管道和支付方考量，重新定義全球痛風治療的模式。

痛風治療領域正經歷著變革性的轉變，影響著臨床實務、商業化和供應鏈的韌性。生物製藥和重組尿酸分解酶製劑的進步為難治性高尿酸血症提供了強力的治療選擇，促使臨床醫生重新評估強化治療方案和治療順序。同時，小分子化學和製劑技術的進步提高了傳統藥物的安全性和耐受性，從而提高了患者的依從性並擴大了門診管理範圍。這些藥理學上的進步與數位醫療的普及應用相融合，包括遠端醫療、遠距監測和患者支援平台，從而擴大了專科醫療服務的覆蓋範圍，並實現了更持續的追蹤。

對2025年美國關稅對痛風藥物供應鏈、採購和定價的影響進行全面分析

美國2025年實施的關稅調整對痛風藥物生態系統產生了多方面的影響，波及成本、採購決策和供應鏈結構。某些藥品原料和成品的關稅上調增加了依賴國際採購活性藥物成分（API）的藥物的到岸成本。隨著採購部門的應對，各機構開始實現供應商多元化，並加速其他API供應商的資格認證，以降低單一來源採購的風險。這些變化迫使企業重新談判合約，並將總到岸成本的考量置於藥品清單和採購決策的首要位置。

關鍵細分觀點揭示了不同藥物類別、給藥途徑和最終用戶的臨床效用、採購行為和分銷動態差異。

從細分觀點，不同藥物類別、給藥途徑、分銷管道、劑型和終端用戶環境之間存在顯著的臨床、商業性和分銷動態差異。在各類藥物中，秋水仙鹼等傳統藥物與非類固醇消炎劑（NSAIDs）並存，後者包括Ibuprofen、Indometacin和萘普生等成熟藥物。其他類別包括重組尿酸酶製劑，如培格洛汀酶和拉司布林酶；促尿酸排泄藥，如苯溴馬隆、雷西納德和丙磺舒；以及黃嘌呤氧化酶抑制劑，包括Allopurinol、非布司他和托吡司他等代表藥物。每類藥物都有其獨特的療效和安全性權衡，這影響著它們在治療流程中的定位。重組尿酸酶製劑通常用於難治性病例，而黃嘌呤氧化酶抑制劑則是慢性降尿酸策略的基礎。

對美洲、歐洲、中東和非洲以及亞太市場的需求促進因素、監管影響和准入挑戰進行區域比較分析

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的藥物可近性、應用和商業策略有顯著影響。在美洲，市場趨勢往往受到私人保險、公共支付方和綜合醫療服務體系相互作用的影響，從而形成多元化的報銷環境，這種環境獎勵那些具有明確臨床差異化和強力的藥物經濟學證據的藥物。製造商通常會投資於病患支援服務和療效記錄，以確保藥物能夠被納入藥品目錄，並在慢性病照護機構中維持較高的用藥依從性。

企業定位和競爭策略塑造了痛風治療領域創新者和成熟製造商之間的產品組合、聯盟和研發投資。

在痛風治療領域，各公司之間的競爭融合了現有產品組合管理、精準創新和策略聯盟。現有製藥企業擁有廣泛的產品組合、深厚的經銷網路，並在複雜的醫保談判方面經驗豐富，這使它們能夠透過產品生命週期管理和製劑改進來鞏固市場地位。同時，生物技術和專科藥物研發企業正在推廣重組尿酸分解酶療法和新型分子療法，以滿足難治性患者群體未被滿足的醫療需求，並透過臨床差異化贏得專科醫生的處方。

為行業領導者提供切實可行的策略建議，以確保供應鏈韌性、最佳化產品系列併調整商業模式以適應不斷變化的相關人員需求。

在痛風治療領域，產業領導者可以採取多項切實可行的措施來鞏固市場地位、保障利潤並改善病患療效。首先，應優先考慮供應鏈韌性，具體措施包括：實現原料藥(API) 和成品藥供應商多元化、建立區域性生產體系，以及透過先進的庫存和物流分析提高供應鏈透明度。這些措施有助於降低關稅波動和地緣政治動盪帶來的風險，同時提高對需求波動的應對力。其次，應最佳化分銷和商業資源配置，確定能夠滿足門診、住院和居家管理需求的劑型和給藥途徑，並制定與臨床路徑相符的產品組合策略。

報告的基本調查方法嚴謹可靠，結合了數據三角測量、同行檢驗、定性和定量技術，以確保得出公正可靠的結論。

本報告的研究採用了多種方法，對來自各種高品質資訊來源的證據進行三角驗證，並透過專家意見檢驗研究結果。主要定性研究包括對臨床醫生、處方集決策者、採購專業人員和供應鏈經理進行結構化訪談，以收集有關治療選擇決定因素、給藥偏好和運營限制的第一手資訊。次要分析綜合了已發布的監管文件、同行評審的臨床文獻和試驗註冊資訊，以記錄關鍵治療領域的臨床和安全性現狀。來自物流和分銷案例研究的營運數據用於評估供應鏈的脆弱性和緩解措施。

對痛風治療生態系統進行全面綜合分析，提煉其對臨床實務、供應鏈策略和商業性決策的啟示

總之，痛風治療領域治療方法，既有成熟治療方法，也有新興療法，同時也面臨監管壓力和營運限制，這給價值鏈上的所有相關人員帶來了風險和機會。臨床創新（特別是重組尿酸酶和改良的黃嘌呤氧化酶抑制劑）正在拓展治療選擇，而病人參與的提高和數位醫療基礎設施的改善正在改變醫療服務模式。同時，政策變革和供應鏈中斷凸顯了韌性、透明的成本模型和策略採購規劃的重要性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依藥物類別分類的痛風治療市場

  • 秋水仙鹼
  • 非類固醇消炎劑
    • Ibuprofen
    • Indometacin
    • 萘普生
  • 重組尿酸酶
    • 佩格洛蒂卡澤
    • 拉斯布里卡澤
  • 尿酸排泄促進劑
    • 苯溴馬隆
    • 萊西努拉德
    • 丙磺舒
  • 黃嘌呤氧化酶抑制劑
    • Allopurinol
    • 非布司他
    • 托吡羅昔康

9. 痛風治療市場（依給藥途徑分類）

  • 靜脈注射
  • 口服
  • 皮下注射

第10章 依劑型分類的痛風治療市場

  • 膠囊
  • 注射液
  • 口服液
  • 藥片

第11章 痛風治療市場依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 痛風治療市場（依最終用戶分類）

  • 門診手術中心
  • 診所
  • 居家醫療
  • 醫院

第13章 各地區痛風治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 痛風治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國痛風治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國痛風治療市場

第17章 中國痛風治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Cipla Limited
  • Hikma Pharmaceuticals PLC
  • Horizon Therapeutics plc
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
  • Torrent Pharmaceuticals Limited
  • Viatris Inc.
Product Code: MRR-AE420CB153DA

The Gout Medications Market was valued at USD 2.98 billion in 2025 and is projected to grow to USD 3.15 billion in 2026, with a CAGR of 6.23%, reaching USD 4.56 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.98 billion
Estimated Year [2026] USD 3.15 billion
Forecast Year [2032] USD 4.56 billion
CAGR (%) 6.23%

An incisive introduction to the current clinical, commercial, and regulatory dynamics reshaping the global gout therapeutics landscape for modern stakeholders

Gout remains a clinically significant and commercially dynamic therapeutic area, shaped by evolving standards of care, emerging biologic and small-molecule options, and changing patterns of patient access. Clinicians continue to balance acute symptom management with long-term urate-lowering strategies, while payers and procurement teams demand evidence that interventions deliver measurable outcomes and cost-efficiencies. Converging innovations in drug development and healthcare delivery have introduced new therapeutic choices and heightened the complexity of adjudicating optimal treatment pathways.

Against this backdrop, stakeholders require a concise yet rigorous introduction that frames current treatment modalities, regulatory environments, and the operational pressures affecting supply and distribution. This introduction contextualizes the interplay between clinical efficacy, safety profiles, route of administration preferences, and the logistical realities of getting therapies from manufacturer to patient. It also outlines the competitive landscape in which established small-molecule treatments coexist with recombinant biologic agents, and in which differentiation is increasingly driven by real-world evidence and patient-centric service bundles.

The reader should emerge from this section with a clear understanding of the foundational dynamics that inform subsequent analysis: the therapeutic categories in play, the key decision points for payers and providers, and the structural drivers of change that will influence strategic choices across the value chain.

Transformative shifts altering patient care pathways, innovation pipelines, and payer considerations that are redefining gout treatment paradigms worldwide

The gout therapeutics landscape is undergoing transformative shifts that affect clinical practice, commercialization, and supply chain resilience. Advances in biologic therapies and recombinant uricase agents have introduced potent options for refractory hyperuricemia, prompting clinicians to reassess escalation pathways and therapeutic sequencing. Simultaneously, improvements in small-molecule chemistry and formulation have refined safety and tolerability profiles for longstanding classes, enabling better adherence and broader outpatient management. These pharmacological advances intersect with digital health adoption, where telemedicine, remote monitoring, and patient support platforms are extending the reach of specialist care and enabling more consistent follow-up.

Concurrently, payer expectations and procurement strategies are evolving toward value-based arrangements that emphasize measurable clinical outcomes and total cost of care. Health systems increasingly demand real-world evidence to justify formulary placement, and this is accelerating investments in observational studies and outcomes registries. At the same time, supply chain considerations have gained prominence: manufacturers and distributors are prioritizing resilience through supplier diversification, regional manufacturing capacity, and strategic inventory management. Regulatory pathways have adapted to reflect these shifts, offering expedited mechanisms for high-need therapeutics and clearer guidance for biosimilars and interchangeability, which in turn alter competitive landscapes. Taken together, these changes are reshaping how therapies are developed, positioned, and delivered, creating both challenges and opportunities for stakeholders seeking sustainable differentiation.

Comprehensive analysis of how recent United States tariff policies enacted in 2025 are cascading through supply chains, procurement, and pricing for gout therapeutics

The tariff changes implemented in the United States in 2025 have exerted a multifaceted influence across the gout medication ecosystem, impacting costs, sourcing decisions, and supply chain configurations. Increased duties on select pharmaceutical inputs and finished products have elevated landed costs for medications that rely on internationally sourced active pharmaceutical ingredients. As procurement teams reacted, organizations initiated supplier diversification and accelerated qualification of alternate API suppliers to mitigate single-source exposure. These shifts forced contract renegotiations and brought total landed cost considerations to the foreground of formulary and procurement deliberations.

In response, some manufacturers examined the feasibility of regionalizing production to reduce tariff-induced volatility, while distributors reassessed inventory strategies to balance availability against capital tied up in safety stock. The tariff environment also influenced pricing dynamics in negotiations with payers and integrated delivery networks, where increased list prices faced heightened scrutiny tied to value demonstration. Moreover, procurement cycles lengthened as buyers sought to understand the long-term implications of policy changes and to incorporate contingency clauses into supplier agreements. Patient access programs and support services became more prominent as manufacturers looked to buffer end users from near-term cost pressures.

Looking ahead, the cumulative effect of these policies has been to elevate the strategic importance of flexible manufacturing, closer supplier relationships, and transparent cost modeling. Stakeholders that prioritize supply chain visibility and proactive sourcing stand better positioned to navigate tariff-driven disruptions while maintaining continuity of care for patients dependent on gout therapeutics.

Key segmentation perspectives that reveal differing clinical utility, procurement behaviors, and distribution dynamics across drug classes, administration routes and end users

A segmentation-focused lens reveals differentiated clinical, commercial, and distribution dynamics across drug classes, administration routes, distribution channels, dosage forms, and end-user settings. Within drug class, traditional agents such as colchicine coexist with Nonsteroidal Anti-Inflammatory Drugs that include well-established options like ibuprofen, indomethacin, and naproxen; recombinant uricase modalities exemplified by pegloticase and rasburicase; uricosuric agents such as benzbromarone, lesinurad, and probenecid; and xanthine oxidase inhibitors with representatives including allopurinol, febuxostat, and topiroxostat. Each class carries unique efficacy and safety trade-offs that influence where it fits in treatment algorithms, with recombinant uricase often reserved for refractory cases while xanthine oxidase inhibitors underpin chronic urate-lowering strategies.

Route of administration considerations-intravenous, oral, and subcutaneous-shape both clinical workflow and patient preference, influencing where therapies are delivered and which stakeholders manage administration. Distribution channel behaviors vary by channel type: hospital pharmacies tend to prioritize on-formulary, inpatient-ready therapies with established tender relationships, online pharmacies focus on convenience and chronic adherence, and retail pharmacies balance front-end accessibility with payer constraints. Dosage form differences across capsules, injectable solutions, oral solutions, and tablets also affect adherence, shelf life, and storage requirements, feeding directly into distribution and inventory planning.

End-user distinctions across ambulatory surgical centers, clinics, home care, and hospitals determine setting-specific demand patterns, reimbursement pathways, and service expectations. For example, therapies requiring intravenous administration concentrate demand within hospital and clinic settings, whereas oral formulations support broader deployment across home care and retail channels. Understanding these segmentation interdependencies is essential for tailoring clinical positioning, commercial outreach, and supply chain strategies to the realities of different stakeholder groups.

Regional intelligence that contrasts demand drivers, regulatory influences, and access challenges across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Regional dynamics exert a powerful influence on access, adoption, and commercial strategy across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, market behavior is frequently shaped by an interplay of private insurance, public payers, and integrated delivery systems, creating heterogeneous reimbursement environments that reward clear clinical differentiation and robust pharmacoeconomic evidence. Manufacturers often invest in patient support services and outcomes documentation to secure favorable formulary status and to sustain adherence in chronic treatment settings.

In Europe, Middle East & Africa, regulatory and pricing frameworks emphasize health technology assessment and cost-effectiveness, encouraging manufacturers to engage early with payers and to demonstrate comparative benefits. Tender processes and national procurement authorities often drive volume-based purchasing decisions, while regional variance in access can create pockets of both advanced biologic uptake and high reliance on generics. Across Asia-Pacific, rapid adoption of innovative therapies in certain markets coexists with cost-sensitive procurement in others, incentivizing manufacturers to calibrate market entry strategies by country and to build local partnerships or manufacturing presence to enhance competitiveness and compliance.

Across all regions, differences in supply chain infrastructure, regulatory timelines, and clinical practice patterns require nuanced approaches to commercialization and distribution. Manufacturers that adapt their go-to-market models to regional payer structures, invest in local evidence generation, and cultivate strategic partnerships are better positioned to navigate the varied landscape and to expand patient access while managing commercial risk.

Corporate positioning and competitive maneuvers shaping portfolios, partnerships, and R&D investments among innovators and established manufacturers in gout therapeutics

Competitive dynamics among companies active in the gout therapeutics space reflect a blend of legacy portfolio management, targeted innovation, and strategic partnerships. Established pharmaceutical manufacturers maintain broad portfolios with deep distribution networks and experience navigating complex payer negotiations, enabling them to defend market positions through lifecycle management and incremental formulation improvements. At the same time, biotechnology firms and specialty developers are advancing recombinant uricase therapies and novel molecular approaches that address unmet needs in refractory patient populations, using clinical differentiation to gain traction among specialist prescribers.

Contract manufacturing organizations and specialty generics producers play critical roles in ensuring supply continuity, executing on cost-efficient production while complying with global regulatory standards. Distributors and specialty pharmacies focus on patient support and adherence programs that improve real-world outcomes and strengthen manufacturer-payer relationships. Across the ecosystem, strategic behaviors such as licensing deals, co-development agreements, and targeted acquisitions are common as organizations seek capabilities they lack internally-whether that is biologics manufacturing, regional access expertise, or digital patient engagement platforms.

Companies that combine clinical development excellence with operational agility, transparent pricing models, and strong real-world evidence packages tend to secure preferential positioning with payers and providers. Those able to integrate upstream manufacturing flexibility with downstream patient services will likely navigate reimbursement pressures more effectively and sustain long-term relationships with health systems and specialty clinics.

Actionable strategic recommendations enabling industry leaders to secure supply resilience, optimize product portfolios, and align commercial models to evolving stakeholder needs

Industry leaders can take several practical actions to strengthen market position, protect margins, and enhance patient outcomes within the gout therapeutics ecosystem. Prioritize supply chain resilience by diversifying API and finished-dose suppliers, establishing regional manufacturing contingencies, and enhancing visibility through advanced inventory and logistics analytics. These measures reduce exposure to tariff fluctuations and geopolitical disruptions while improving responsiveness to demand shifts. Simultaneously, align portfolio strategy to clinical pathways by identifying which formulations and administration routes match the needs of ambulatory care, hospital settings, and home-based management, thereby optimizing channel-specific distribution and commercial resource allocation.

Engage proactively with payers and health technology assessment bodies to build compelling value dossiers grounded in real-world evidence and comparative effectiveness studies. Invest in patient support programs and adherence tools that demonstrate measurable outcomes, as these services can influence formulary decisions and reduce total cost of care. Consider strategic partnerships with biotech innovators to access recombinant or biologic capabilities, and use licensing or joint-development agreements to expand therapeutic breadth without disproportionate capital investment. Finally, adopt flexible commercial models that include outcomes-based contracting where appropriate, and leverage digital engagement to improve patient education and follow-up. Implementing these steps will strengthen negotiating positions, improve patient retention, and create defensible differentiation in a crowded therapeutic field.

Robust research methodology outlining data triangulation, expert validation, and qualitative and quantitative techniques employed to ensure impartial and reliable insights

The research underpinning this report employed a multi-method approach designed to triangulate evidence from diverse, high-quality sources and to validate findings through expert input. Primary qualitative inquiry included structured interviews with clinicians, formulary decision-makers, procurement specialists, and supply chain leaders to capture firsthand perspectives on therapeutic choice drivers, administration preferences, and operational constraints. Secondary analysis synthesized publicly available regulatory filings, peer-reviewed clinical literature, and trial registries to document the clinical and safety landscape for key therapeutic classes. Operational data from logistics and distribution case studies informed assessments of supply chain vulnerabilities and mitigation strategies.

Analytical methods combined thematic coding of qualitative data with comparative assessment frameworks that evaluated therapeutic differentiation, channel suitability, and regional access factors. Findings were iteratively reviewed with subject matter experts to ensure interpretive accuracy and to surface nuances that raw data alone might obscure. Where possible, real-world evidence and outcomes studies were used to corroborate claims about adherence, tolerability, and setting-of-care impacts. The methodology places emphasis on transparency: assumptions are documented, limitations are acknowledged, and confidence levels are indicated for insights that rely on evolving or incomplete datasets. Ethical standards for research conduct were maintained throughout, with care taken to protect interviewee anonymity and to avoid conflicts of interest in source selection.

Concluding synthesis that distills implications for clinical practice, supply chain strategy, and commercial decision-making in the gout medication ecosystem

In conclusion, the gout therapeutics landscape presents a complex blend of established and emerging treatments, regulatory pressures, and operational constraints that together create both risk and opportunity for stakeholders across the value chain. Clinical innovation-most notably in recombinant uricase and refined xanthine oxidase inhibition-has expanded therapeutic options, while improvements in patient engagement and digital health infrastructure are reshaping delivery models. At the same time, policy shifts and supply chain disruptions underscore the importance of resilience, transparent cost modeling, and strategic sourcing.

For decision-makers, the imperative is to translate these insights into concrete actions: refine portfolio priorities to match setting-specific needs, deepen engagement with payers through robust evidence generation, and shore up supply chains to withstand policy-driven perturbations. Organizations that integrate clinical differentiation with operational agility and patient-centric services will be better positioned to secure favorable formulary placement and to deliver consistent care. The report's synthesis equips leaders with the context and recommendations needed to make informed choices that balance clinical benefit, access, and commercial viability in an evolving market environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gout Medications Market, by Drug Class

  • 8.1. Colchicine
  • 8.2. Nonsteroidal Anti-Inflammatory Drugs
    • 8.2.1. Ibuprofen
    • 8.2.2. Indomethacin
    • 8.2.3. Naproxen
  • 8.3. Recombinant Uricase
    • 8.3.1. Pegloticase
    • 8.3.2. Rasburicase
  • 8.4. Uricosuric Agents
    • 8.4.1. Benzbromarone
    • 8.4.2. Lesinurad
    • 8.4.3. Probenecid
  • 8.5. Xanthine Oxidase Inhibitors
    • 8.5.1. Allopurinol
    • 8.5.2. Febuxostat
    • 8.5.3. Topiroxostat

9. Gout Medications Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Gout Medications Market, by Dosage Form

  • 10.1. Capsules
  • 10.2. Injectable Solutions
  • 10.3. Oral Solutions
  • 10.4. Tablets

11. Gout Medications Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Gout Medications Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Home Care
  • 12.4. Hospitals

13. Gout Medications Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Gout Medications Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Gout Medications Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Gout Medications Market

17. China Gout Medications Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Cipla Limited
  • 18.6. Hikma Pharmaceuticals PLC
  • 18.7. Horizon Therapeutics plc
  • 18.8. Lupin Limited
  • 18.9. Novartis AG
  • 18.10. Pfizer Inc.
  • 18.11. Takeda Pharmaceutical Company Limited
  • 18.12. Teva Pharmaceutical Industries Limited
  • 18.13. Torrent Pharmaceuticals Limited
  • 18.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GOUT MEDICATIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GOUT MEDICATIONS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GOUT MEDICATIONS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GOUT MEDICATIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GOUT MEDICATIONS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GOUT MEDICATIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY COLCHICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY COLCHICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY COLCHICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INDOMETHACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INDOMETHACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INDOMETHACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY PEGLOTICASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY PEGLOTICASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY PEGLOTICASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RASBURICASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RASBURICASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RASBURICASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY BENZBROMARONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY BENZBROMARONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY BENZBROMARONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY LESINURAD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY LESINURAD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY LESINURAD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY PROBENECID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY PROBENECID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY PROBENECID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ALLOPURINOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ALLOPURINOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ALLOPURINOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY FEBUXOSTAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY FEBUXOSTAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY TOPIROXOSTAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY TOPIROXOSTAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY TOPIROXOSTAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ORAL SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ORAL SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. GCC GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 196. GCC GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 197. GCC GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 198. GCC GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. GCC GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 201. GCC GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. GCC GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. G7 GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 226. G7 GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 227. G7 GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 228. G7 GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. G7 GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 231. G7 GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. G7 GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. NATO GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 236. NATO GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 237. NATO GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. NATO GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 241. NATO GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. NATO GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL GOUT MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES GOUT MEDICATIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA GOUT MEDICATIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA GOUT MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA GOUT MEDICATIONS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA GOUT MEDICATIONS MARKET SIZE, BY RECOMBINANT URICASE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA GOUT MEDICATIONS MARKET SIZE, BY URICOSURIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA GOUT MEDICATIONS MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA GOUT MEDICATIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA GOUT MEDICATIONS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA GOUT MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA GOUT MEDICATIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)